Tuesday 9:15am Update: The (Mini) Golden Cross and MACD Indicate Potential Upswing
Additionally, we’re viewing LuxAlgo’s Premium indicator, which shows a buy signal on the one-day time frame and near the bottom of an accumulation zone. (Portrayed in green layers below the candle.) Overall, we see strong set ups on the short time frames and a potential daily reversal.
Our recent focus, NeuroOne Medical Technologies Corp (NMTC), has shown some exciting developments on the technical front. The Moving Average Convergence Divergence (MACD) is presenting a strong setup, suggesting a potential bullish trend in the near future. But there’s more to the story.
A critical technical indicator known as a “Mini Golden Cross” is appearing on the 1-hour time frame. For those new to the term, a Mini Golden Cross occurs when a short-term moving average (like the 9-day MA) crosses above a long-term moving average (like the 21-day MA). This is typically seen as a bullish signal in technical analysis and often indicates the potential for an uptrend.
With these strong indicators, we are very excited about the potential next steps for NMTC. As always, we encourage you to continue your research and keep a close eye on these developments.
Full Report, Disclaimers and Yesterdays Updates Below.
Hello NMTC enthusiasts,
We’re excited to bring to your attention some encouraging technical indicators we’ve noticed on the 4-hour and 1-day charts for NMTC. As always, this is not financial advice, but we believe in empowering our readers with all the available information.
Upon analyzing the technical, we are seeing an extremely strong foundation setting. The MACD (Moving Average Convergence Divergence) – a trend-following momentum indicator – is currently showing signs of a potential reversal. This could indicate a shift from a bearish to a bullish trend, a promising sign for investors looking for an upward swing in NMTC.
In addition, the William VIX Fix, often used as a bottom finder, has triggered a potential bottom (as shown by the green lines in the second-to-last image). This could suggest that NMTC has hit its low point and might be poised for a bounce back.
Interestingly, the last time we saw the MACD showing this level of strength into a convergence, it resulted in an impressive upside swing of over 40%! If history repeats itself, we could be in for a substantial positive price movement.
While these indicators are promising, remember that investing always carries risk. Always conduct your own research and consider your personal financial situation and risk tolerance before making any investment decisions.
Stay tuned for more updates and happy investing!
Virtus Junxit: Reiterate MUST Add to Watchlist $NMTC
First of all, if you’ve been on a different planet and missed our last 6 featured profiles then let us give you an quick synopsis of why we’re so excited:
- DFLI: April 4th Alert – High of approx $3.43 – April 18th Post Alert High of approx $6.35 (Roughly 86% Swing)
- HILS: April 10th Alert -High of approx $0.92 – April 11th Post Alert High of approx $1.33 (Roughly 44% Swing)
- BTCY: April 14th Friday High of approx $0.53 – April 19th Post Alert High of approx $0.85 (Roughly 60% Swing)
- GNPX April 17th Close of approx .93 – April 18th High of approx $1.15 (Roughly 24% Swing)
- CTXR – Intraday – April 24th Alerted Potential Support of $1.35 – 24th low of approx $1.34 and high of approx $1.62 (Roughly 20% intraday swing)
- EZFL – May 5th Close of approx $2.23 – May 8th Alert – High of approx $3.97 (Roughly 77% Swing)
Reviewing you can quickly see that while there’s been explosive price action they have all been situations best suited for experienced day traders. We would like to reiterate that we are not licensed to give investment or tax advice and any readers of this publication or any of our curated content should always consult with their investment advisors and conduct your own independent research.
Hold onto your hats! We’ve got an exhilarating tale to tell. It’s about our Past Champ $NMTC making waves in the field of medical technology – NeuroOne Medical Technologies. They’ve made significant strides in their Q1 FY2023, and we believe the journey is only just beginning.
NeuroOne has been busy blowing our expectations out of the water. The star of the show for Q1 FY2023 was a revenue figure that reached $0.5 million, surging past our modest $0.3 million expectation. This unexpected climb up the revenue ladder was primarily due to the successful launch of their groundbreaking Evo sEEG electrode product line in partnership with Zimmer Biomet. The result? A surprising twist – a gross margin that’s ventured into the green with 6.8%, a far cry from the forecasted (22.3%). Yes, there was a slight hiccup with a net loss of ($3.5) million, but nothing that wasn’t on our radar. With $4.6 million in cash and equivalents and a clean slate with no debt, NeuroOne is strategically positioned for growth.
Product or Service Analysis:
Now, let’s talk about the tech that’s making all the difference. The Evo sEEG launch has been met with an applause that resonates throughout the medical community. We’re talking about a product that’s already making its mark, with multiple successful procedures under its belt. Clinicians seem to be all praise for its tactile feel, waveform clarity, and the immaculate imagery under CT scans. But wait, there’s more. The OneRF ablation system, a marvel designed to perform therapeutic ablation right after diagnosis with the same Evo sEEG electrodes, is prepping for its grand debut with an impending FDA submission. The buzz around this technology is palpable with several big names expressing interest.
Mayo Clinic’s Clinical Investment Interest:
In recent financial news, the prestigious Mayo Clinic has demonstrated significant interest in NeuroOne Medical Technologies Corp. As a globally recognized leader in healthcare, research, and innovation, Mayo Clinic’s investments are often seen as strong indicators of potential success in the healthcare sector. During Q2 of 2021, Mayo Clinic added NeuroOne Medical Technologies to its portfolio, marking a noteworthy vote of confidence in the company’s growth potential and its innovative approach to treating neurological disorders. This development further establishes NeuroOne’s position in the medical technology field and may be indicative of the company’s future trajectory.
The involvement of Mayo Clinic is not only a testament to NeuroOne’s current success but also a promising indicator of the company’s potential for future growth and advancement in the field of medical technologies.
The Prestige of Mayo Clinic:
Mayo Clinic is a renowned medical institution that holds an esteemed position in the global healthcare landscape. With a reputation built on over a century of groundbreaking research, exceptional patient care, and medical education, Mayo Clinic is a powerhouse in the field.
But what’s a good story without a hint of suspense? NeuroOne is up against some challenges. Supplier disruptions could put a damper on product availability, and the journey to bring the OneRF technology to fruition requires either a strategic partner or significant capital.
Conclusion and Recommendation:
This narrative of financial success, innovative product launches, and potential market disruption makes NeuroOne a compelling protagonist in the world of medical tech. We’re all over this dark horse and reiterating the addition of this name to your watchlist.
The unfolding story of NeuroOne promises to be a thrilling ride for those bold enough to join the journey. Yet, as with any adventure, it’s vital to be aware of the potential pitfalls.
So, intrigued? We bet you are! It’s time to dive deep, dig around, and see what other treasures you can unearth about NeuroOne. After all, there’s nothing quite like the thrill of discovering an untapped potential and being the first to shout about it from the rooftops. Let the exploration begin…we’ll be updating as the day progresses.
Virtus Junxit Team